Search

Robert R Korngold

from Naples, FL
Age ~71
Get Report
Also known as:
Robert D Korngold, Robt Korngold, Rob D Korngold, Bob D Korngold, Debra Korngold
Related to:
Gilly V KorngoldRoger N Gladstone, 70Eileen MintzNancy Goosman, 74Barbara Kelston, 82Mary Kelston
Connected to:
Adam M Korngold, 41Andrew V Kornhaber, 41Alain L Kornhauser, 79Chris Kornhaus, 69Diane G Kornick, 77Julia Kornich, 50Lacey I Kornicki, 41Oleg V Kornienko, 57Olga Y Kornienko, 45Peggy L Kornis, 64

Robert Korngold Phones & Addresses

  • Naples, FL
  • 16 Cambridge Pl, Wayne, NJ 07470
  • Woodland Park, NJ
  • 101 Dalton Ter, Cherry Hill, NJ 08003 (856) 424-7623
  • Voorhees, NJ
  • Paterson, NJ
  • Woodland Park, NJ
  • Clementon, NJ

Resumes

Resumes

Robert Korngold Photo 1

Robert Korngold

View page
Location:
Greater New York City Area
Industry:
Marketing and Advertising
Robert Korngold Photo 2

Ceo At Montessori Home

View page
Location:
Greater New York City Area
Industry:
E-Learning

Business Records

Name / Title
Company / Classification
Phones & Addresses
Robert D. Korngold
Principal
Family Literacy Groups Inc
School/Educational Services
25 Roxbury Rd, Scarsdale, NY 10583
Robert D. Korngold
Chief Executive Officer, President
MONTESSORI HOME, INC
Business Consulting Services · Advertising Agencies
25 Roxbury Rd, Scarsdale, NY 10583
(914) 472-9849

Publications

Us Patents

Peptide Mimics Of The Cytokine Receptor Common Chain And Methods And Compositions For Making And Using The Same

View page
US Patent:
6346602, Feb 12, 2002
Filed:
Feb 6, 1998
Appl. No.:
09/020065
Inventors:
Robert Martin Townsend - Boothwyn PA
Robert Korngold - Cherry Hill NJ
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
A61K 3812
US Classification:
530317, 530300, 514 9, 514 11
Abstract:
Peptides which mimic a loop on the -chain that either interact with a cytokine or a -chain partner receptor chain of a heterodimeric cytokine receptor are disclosed. The peptides consist of 5-25 amino acids and inhibit signal transduction mediated by cytokine:receptor binding of cytokines that bind to receptors that comprise a -chain. Pharmaceutical compositions that comprise the peptides are disclosed. Methods of inhibiting signal transduction mediated by cytokine:receptor binding of cytokines that bind to receptors that comprise a -chain, methods of inhibiting cytokine mediated cell growth, proliferation, function or activity, methods of treating patients suffering from a disease disorder or condition characterized by cytokine mediated cell growth, proliferation, function or activity and methods of preventing a condition characterized by cytokine mediated cell growth, proliferation, function or activity are disclosed.

Cd4-Derived Peptides That Inhibit Immune Response

View page
US Patent:
6844421, Jan 18, 2005
Filed:
Dec 7, 1998
Appl. No.:
09/206786
Inventors:
Robert Korngold - Cherry Hill NJ, US
Ziwei Huang - Philadelphia PA, US
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
A61K 3800
A61K 3804
US Classification:
530328, 530329, 530330
Abstract:
The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4 T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4 T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C-C′ loop of the D1 domain; residues 317-323, the C-C′ loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.

Mimetics Of Cd4 That Inhibit Immune Response

View page
US Patent:
7345020, Mar 18, 2008
Filed:
May 7, 2004
Appl. No.:
10/841050
Inventors:
Robert Korngold - Cherry Hill NJ, US
Ziwei Huang - Champaign IL, US
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
A61K 38/08
A61K 38/12
C07K 4/00
A61K 38/00
A61K 38/04
US Classification:
514 11, 514 17, 514183, 530323, 530332, 930270
Abstract:
The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4 T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4 T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C—C′ loop of the D1 domain; residues 317-323, the C—C′ loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.

L-Leucyl-L-Leucine Methyl Ester Treatment Of Donor Lypmhocyte Infusions In Bone Marrow Transplant Patients

View page
US Patent:
20010036664, Nov 1, 2001
Filed:
Mar 9, 2001
Appl. No.:
09/803223
Inventors:
Robert Korngold - Cherry Hill NJ, US
Neal Flomenberg - Cherry Hill NJ, US
Michael Hsieh - Philadelphia PA, US
International Classification:
C12N005/08
US Classification:
435/372000, 424/093700
Abstract:
The present invention relates to a method of inhibiting graft-versus-host disease in allogeneic hematopoietic stem cell transplant (HSCT) patients by using L-leucyl-L-leucine methyl ester (LLME) to eliminate selective cytotoxic T cells in donor lymphocyte infusions (DLI). LLME has been shown to inhibit GVHD in animal models by selectively inducing apoptosis in natural killer cells and cytotoxic T cells. The application of LLME to the human clinical HSCT situation, however, has been hampered by HSC toxicity when unseparated marrow is treated at the concentrations necessary to purge GVHD-inducing T cells prior to infusion. In the present invention, this problem is circumvented by the LLME ex vivo treatment of DLI administered following transplantation of T cell-depleted HSC. In this setting, the effects of LLME on HSC contained within the DLI are irrelevant for clinical outcome. In another embodiment, the risk of toxicity to the stem cell population is avoided by ex vivo LLME treatment of donor lymphocytes after separation of CD34 stem cells and then co-administration of the LLME-treated donor CD34 fraction and the untreated CD34 stem cells.

Peptide Mimics Of The Cytokine Receptor Common Gamma Chain And Methods And Compositions For Making And Using The Same

View page
US Patent:
20040092709, May 13, 2004
Filed:
Jun 29, 2001
Appl. No.:
09/896784
Inventors:
Robert Townsend - Boothwyn PA, US
Robert Korngold - Cherry Hill NJ, US
Swati Choksi - Broomal PA, US
Assignee:
Thomas Jefferson University
International Classification:
C07K007/08
C07K007/06
US Classification:
530/328000, 530/329000
Abstract:
Peptides which mimic a loop on the -chain that either interact with a cytokine or a -chain partner receptor chain of a heterodimeric cytokine receptor are disclosed. The peptides consist of 5-25 amino acids and inhibit signal transduction mediated by cytokine:receptor binding of cytokines that bind to receptors that comprise a -chain. Pharmaceutical compositions that comprise the peptides are disclosed. Methods of inhibiting signal transduction mediated by cytokine:receptor binding of cytokines that bind to receptors that comprise a -chain, methods of inhibiting cytokine mediated cell growth, proliferation, function or activity, methods of treating patients suffering from a disease disorder or condition characterized by cytokine mediated cell growth, proliferation, function or activity and methods of preventing a condition characterized by cytokine mediated cell growth, proliferation, function or activity are disclosed.

Cd-4 Derived Peptides That Inhibit Immune Responses

View page
US Patent:
58469338, Dec 8, 1998
Filed:
Jun 28, 1996
Appl. No.:
8/672610
Inventors:
Robert Korngold - Cherry Hill NJ
Ziwei Huang - Philadelphia PA
International Classification:
A61K 3800
US Classification:
514 11
Abstract:
The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4. sup. + T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4. sup. + T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C-C' loop of the D1 domain; residues 317-323, the C-C' loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.

Use Of Cd4-Binding Small Molecules To Inhibit Immune Responses

View page
US Patent:
61273872, Oct 3, 2000
Filed:
Dec 9, 1997
Appl. No.:
8/987086
Inventors:
Ziwei Huang - Philadelphia PA
Robert Korngold - Cherry Hill NJ
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
A61K 31425
US Classification:
514330
Abstract:
The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4. sup. + T cell immune responses by identifying compounds that block the interaction of CD4 and class II MHC gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4. sup. + T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 500 and 150 that bind to the GFCC'C" portion of the D1 domain of human CD4 lymphocyte cell surface antigen.

Peptides That Inhibit T Cell Activation And Methods Of Using The Same

View page
US Patent:
56458371, Jul 8, 1997
Filed:
Jan 17, 1995
Appl. No.:
8/372952
Inventors:
Bradford A. Jameson - Philadelphia PA
Swati Choksi - Broomall PA
Robert Korngold - Cherry Hill NJ
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
A61K 3812
C07K 512
US Classification:
4241851
Abstract:
Compounds that inhibit CD8 mediated T cell activation and that have a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 53-56 and/or 60-67 and pharmaceutical compositions comprising such compounds are disclosed. Method of inhibiting activation of a human T cell are disclosed. The methods comprise contacting a T cell with a compound that inhibits CD8 mediated T cell activation and that has a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 53-56 and/or 60-67. Methods of treating an individual suspected of suffering from or susceptible to graft versus host disease and/or organ rejection are disclosed. The methods comprise administering an effective amount of a compound that inhibits CD8 mediated T cell activation and that has a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 53-56 and/or 60-67.
Control profile
Robert R Korngold from Naples, FL, age ~71 Get Report